Sequential VAD (Vincristine, Adriamycin, Dexamethasone) and VTD (VELCADE®, Thalidomide, Dexamethasone) Induction Followed by High-Dose Therapy with Autologous Stem Cell Transplantation and Maintenance Treatment with VELCADE for Newly Diagnosed Multiple Myeloma: Interim Results of Phase II Trial.
Year: 2007
Type: article
Study design: Clinical Trial
Source: Blood
Institutions: Seoul National University Hospital, National Cancer Center, National Cancer Center Hospital, Ajou University Hospital, Ajou University Medical Center, Korea Institute of Radiological and Medical Sciences, Inha University, Inha University Hospital, Samsung Medical Center, Gachon University Gil Medical Center, Chung-Ang University Hospital, Yonsei University, Severance Hospital, Yonsei University Health System, Ewha Womans University, Ewha Womans University Seoul Hospital, Asan Medical Center, Soonchunhyang University Hospital Seoul
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2570366246